EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization Meeting Abstract
| Authors: | Lencioni, R.; Kudo, M.; Erinjeri, J.; Qin, S.; Ren, Z.; Chan, S.; Arai, Y.; Heo, J.; Mai, A.; Escobar, J.; Chuken, Y. A. L.; Yoon, J. H.; Tak, W. Y.; Suttichaimongkol, T.; Bouattour, M.; Lin, S. M.; Żotkiewicz, M.; Udoye, S.; Cohen, G.; Sangro, B. |
| Abstract Title: | EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization |
| Meeting Title: | 2024 ASCO Gastrointestinal Cancers Symposium |
| Keywords: | 613-225-313; 281-318-430; 261-2388-2665-6735; 283-424-425; 613-225-3248-9559-9794; 3282-3306-7927-3999; 281-9641-2654-9244-11272; 38092-17498; 38092-26368 |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 3 Suppl. |
| Meeting Dates: | 2024 Jan 18-20 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-01-20 |
| Language: | English |
| ACCESSION: | WOS:001266680500143 |
| DOI: | 10.1200/JCO.2024.42.3_suppl.LBA432 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: LBA432 -- Source: Wos |
